Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Palladio Biosciences

Request full access

Biotechnology company with a mission to develop transformative medicines for orphan diseases of the kidney

Washington DC, United StatesFounded 2015Biotech & Life Sciences

About Palladio Biosciences

Palladio Biosciences is a biopharmaceutical company focused on developing innovative treatments for autosomal dominant polycystic kidney disease (ADPKD), a serious genetic disorder that leads to kidney failure. The company's lead drug candidate, lixivaptan, is currently in Phase 3 clinical trials. Lixivaptan aims to provide a safer alternative to existing treatments by reducing liver toxicity, a significant side effect associated with the only currently approved medication for ADPKD. Palladio Biosciences serves patients diagnosed with ADPKD, a market with over 140,000 individuals in the United States alone. The company operates within the biopharmaceutical sector, focusing on research and development to bring new therapies to market. Palladio's business model involves conducting clinical trials to demonstrate the safety and efficacy of lixivaptan, with the goal of obtaining regulatory approval and commercializing the drug. Revenue generation will primarily come from the sale of lixivaptan upon approval. The company is also exploring additional indications and potential partnerships to expand its market reach.

Source: Dealroom company data

At a glance

Status
Acquired
Employees
20
Open positions
None listed
Dealroom signal
55.5/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
Business model
Manufacturing
Client focus
B2B
Links
Website

Funding history

4 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
ACQUISITION✓Exit Feb 2021 $0 — Centessa Pharmaceuticals ↗
SERIES B✓Equity / VC Sep 2020 $20M $80M Roche Venture Fund · Samsara BioCapital · Osage University Partners · Medicxi —
Showing the latest 2 of 4 recorded eventsBook a demo for the full funding history →

Growth signals

Palladio Biosciences website traffic

Latest recorded traffic for Palladio Biosciences is 3.6K monthly website visits, up 2150% over the last three months. Palladio Biosciences's team grew 0% over the past year.

Latest monthly visits3.6K 3-month web change+2150% 1-year team growth0%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

CompanyHeadquartersStatusEmployeesTotal fundingValuation
Harness TherapeuticsA private biotechnology company, headquartered in Cambridge-UK, focused on the development of a novel class of therapeutic RNAs Babraham, United Kingdom Operational 5 $35M $90M
Ziphius VaccinesAddresses urgent global public health needs by developing mRNA-based vaccines Ghent, Belgium Operational
KimialysDeveloper of an analytical device intended to offer products based on innovative surface chemistry in the field of biosensors Paris, France Operational
SideROSFocused on accelerated development of innovative small molecules targeting tumour cells metabolism in high-risk cancers Paris, France Closed
AntegenesGenetic tests for personalized cancer risk prevention Tartu, Estonia Operational
Brenus PharmaProducing the widest panel of tumor associated antigens and resistance markers with a chemical labeling enable to induce cell death by patients' immune system Clermont-Ferrand, France Operational
Akston BiosciencesLeverages its core expertise of designing novel fusion proteins to develop and manufacture new classes of biologic therapeutics for Type 1 diabetes (T1D) prevention, ultra-long acting insulin therapy, and vaccines Beverly, United States Operational
Exeliom BiosciencesDeveloping single bacterial strain drug candidates to deliver first-in-class microbiome-based therapeutics Dijon, France Operational
Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Palladio Biosciences in the Washington DC ecosystem

Live from Dealroom

The Palladio Biosciences office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

5 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A4 investors entered at this stage

  • Medicxi
  • Samsara BioCapital
  • Roche Venture Fund
  • Osage University Partners

Other known investors1 additional known investor

  • Centessa Pharmaceuticals
Team profiled 3 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇺🇸 United States · Washington DC HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Palladio Biosciences on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Palladio Biosciences’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.